Table 2.
Health summary for calves treated with tildipirosin in combination with transdermal flunixin (FTD) or tildipirosin alone (PLBO) at arrival
| FTD | FTD | FTD | PLBO | PLBO | PLBO | |
|---|---|---|---|---|---|---|
| Item | n | % | d | n | % | d |
| Total morbidity | 33.3 | 27.6 | ||||
| BRD first treatment | 61 | 31.8 | 51 | 26.6 | ||
| BRD second treatment | 25 | 13.0 | 21 | 10.9 | ||
| BRD third (chronic) | 4 | 2.1 | 6 | 3.1 | ||
| First treatment success rate | 56.3 | 58.8 | ||||
| BRD observations not treated | 14.6 | 12.0 | ||||
| Days to first BRD pull | 12.4 | 11.9 | ||||
| Treated for lameness | 4 | 2.1 | 3 | 1.6 | ||
| Other treatment | 1 | 0.5 | 2 | 1.0 | ||
| BRD mortality | 10 | 5.2 | 7 | 3.6 | ||
| Non-BRD mortality | 1 | 0.5 | 1 | 0.5 | ||
| Overall mortality | 11 | 5.7 | 8 | 4.2 | ||
| BRD removal | 4 | 2.1 | 6 | 3.1 | ||
| Non-BRD removal | 2 | 1.0 | 3 | 1.6 | ||
| Overall removal | 6 | 3.1 | 9 | 4.7 |
There were no significant differences between treatment groups (P ≤ 0.05).